~~<i id='CD51EF9BA1'><strike id='CD51EF9BA1'><tt id='CD51EF9BA1'><pre id='CD51EF9BA1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：fashion 2025-08-12 08:30:16 - browse：499

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Prosthetic arm enables patients to feel the objects they grip

explore

leisure time

Wikipedia

leisure time

focus

AnewstudydocumentshowFusobacteriummightspurthedevelopmentofendometriosis.V.R.Dowell/CDCEndometriosis

WSS

iTeos Therapeutics debuts first data on TIGIT

Biohaven protein

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Akili, maker of video game for ADHD, to be acquired for 34 million

Bacterial infection may be ‘key event’ in endometriosis, study says

Focused ultrasound for uterine fibroids: an uphill battle

Wikipedia

entertainment

explore

Dobbs anniversary: the lost opportunity of abortion as health care

New case study details death in closely watched Alzhiemer's trial

Drug repurposing or repositioning? The language matters

Listen: PBM conflicts, RSV vaccines, & the future of flu season

State Dept. review finds Biden bears some blame for Afghanistan failures

Latest bird flu infection made farmworker sicker than earlier cases

Medicare details structure of new drug price negotiation program

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Akili, maker of video game for ADHD, to be acquired for 34 million

leisure time

Pfizer's Covid pill remains 89% effective in final analysis, company says

Inside the fall of star MIT scientist David Sabatini

Meta looks to target Twitter with a rival app called Threads

Health insurers say they are turning to AI to cut costs, improve care

Latest bird flu infection made farmworker sicker than earlier cases

iTeos Therapeutics debuts first data on TIGIT

Wikipedia

leisure time

focus

focus